In group 1, patients with hyperuricemia showed a significantly higher platelet surface expression of activated GPIIb/IIIa in response to ADP and higher levels of sCD40L than those without hyperuricemia (activated GPIIb/IIIa: 13.7 MFI (8–22 MFI] vs. 9.7 MFI (6.2–14.6 MFI), p < 0.001; sCD40L: 277.1 pg/mL (181.4–493.3 pg/mL) vs. 171.7 pg/mL (95.1–320.8 pg/mL), p = 0.002). Here, ITGA2B is linked to hyperuricemia.